分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

The VgrG2 effector of Acinetobacter baumannii mediates immune evasion by repressing Csu pilus assembly and triggering phagocyte methuosis

Xu Wenzeng, Zhou Jiancang, Zhang Wang, Jiang Yan, Xu Qingye, Liu Xiaochen, Zhang Yisha, Tan Xiaoxiang, Zhou Junxin, Cui Luyun, Yao Yake, Liang Liang, Xu Chengying, Hua Xiaoting, Yu Yunsong, Zhou Hua

Journal:Nature Communications

IF:18.1

DOI:10.1038/s41467-026-75868-y

PMID:42649145

Published:2026-07-27

research field:肿瘤学生物医学工程药学呼吸生物学纳米技术癌症治疗生物化学

Abstract

Acinetobacter baumannii is a formidable nosocomial pathogen whose multidrug resistance and immune evasion capabilities present a major therapeutic challenge. This study identifies the type VI secretion system (T6SS) effector VgrG2 as a critical virulence regulator in A. baumannii . VgrG2 employs a two-pronged strategy to undermine host innate immunity. First, it transcriptionally represses the major adhesin Csu pilus, reducing bacterial recognition, phagocytic uptake, and neutrophils recruitment. Second, VgrG2 directly targets and hyperactivates the small GTPase Rac1 within phagocytes. This leads to actin cytoskeletal disarray, which drives excessive macropinocytosis, resulting in compromised phagocytosis and methuosis—a non-apoptotic, vacuole-dependent death specific to phagocytes. Thus, VgrG2 selectively eliminates key immune sentinels and alters pulmonary inflammation, promoting bacterial persistence and dissemination. These findings extend the role of T6SS effectors beyond interbacterial competition to include sophisticated eukaryotic-directed attacks, and highlight the VgrG2-Rac1 axis as a promising therapeutic target.

本文使用的Yeasen产品

购物车
客服
转染试用